Prepping for big heart drug launch, Novartis cuts 200 primary care sales staffers

Even a megablockbuster launch isn't enough to save Novartis ($NVS) sales reps targeted for job cuts. The company is laying off 200 primary care sales folks in New Jersey as it rejigs its sales operation and prepares to launch LCZ696, a hotly anticipated heart failure drug. Report